We read with interest the article by Miyata and colleagues 1 (February 2013) in which the authors reported that lovastatin attenuates lung infl ammation in a rabbit model by attenuating macrophage and neutrophil recruitment and activation. We outline here why this is such an important fi nding.
Statins Reduce Lung Infl ammation by Promoting the Clearance of Particulate Matter From Lung Tissues

To the Editor:
We read with interest the article by Miyata and colleagues 1 (February 2013) in which the authors reported that lovastatin attenuates lung infl ammation in a rabbit model by attenuating macrophage and neutrophil recruitment and activation. We outline here why this is such an important fi nding.
There is growing interest in the potential role of statins as adjunct therapy in COPD. Human and animal studies suggest that statins reduce both pulmonary and systemic infl ammation, which is characterized by reductions in IL-8, IL-6, and C-reactive protein. 2 In a published review, we suggested that this immunomodulatory effect is directed by the bronchial epithelium, mediated primarily through the innate immune system (neutrophils and macrophages), and critical to the pathobiology underlying chronic aeropollutant-induced airway disease (eg, COPD) ( Fig 1 ) . 2 This might partly explain why corticosteroid treatment, targeting primarily the adaptive immune system, does not signifi cantly improve important clinical outcomes in COPD, such as slowing the progression of disease or reducing mortality. The study by Miyata et al 1 elegantly demonstrates that inhibition of the innate immune system has an important effect on the response of the lungs to chronic aeropollutant exposure and how this may be inhibited through systemic-based therapy.
The importance of the fi nding that statin therapy effectively inhibits both pulmonary and systemic infl ammation goes beyond high-density lipoprotein cholesterol levels. It remains unclear whether OSA or excessive daytime sleepiness affects objectively measured physical activity. In a recent study, men with untreated OSA had less metabolic improvement than obese patients without OSA after a 1-year healthy eating and physical activity/exercise intervention program. 2 A previous randomized controlled trial found no increase in daytime physical activity under CPAP therapy, despite improvement in daytime sleepiness. 3 There is no established method to best identify physical activity in patients with OSA, obesity, or both. A limited agreement has been found between self-reported questionnaires on physical activity and objective activity measurement with wrist actigraphy. 4 It would have been very diffi cult to objectively measure physical activity in the large sample of our multisite study. Further studies are required to evaluate the contribution of physical activity on dyslipidemia in patients with OSA.
As mentioned by Dr Balta and colleagues, there is growing evidence in support of an independent association between OSA and cardiovascular diseases. Therefore, we entered into our multivariate regression analyses most cardiovascular diseases associated with OSA, including hypertension, ischemic heart disease, cardiac arrhythmia, congestive heart failure, and stroke. Recently, a high prevalence of OSA was observed in patients needing surgery for peripheral arterial disease. 5 We acknowledge that a medical history of peripheral arterial disease has not been recorded in our database. Screening for pulmonary hypertension requires additional investigation, such as echocardiography. In isolation, OSA typically causes only mild pulmonary hypertension that does not require specifi c treatment. We acknowledge that renal, hepatic, and thyroid dysfunction may be observed in patients with OSA; however, in our large multisite study, biologic investigations were limited to those recommended by French guidelines for the management of OSA in routine practice, including fasting blood glucose, glycated hemoglobin, and fasting serum lipid levels. that of COPD. 2 Evidence from a large prospective study of patients with COPD showed that systemic infl ammation conferred its greatest risk on susceptibility to lung cancer. 3 A recent population-based study showed that statin therapy reduced mortality for a number of cancers by about 20% to 30%, particularly those linked with smok ing and obesity. 4 In absolute terms, we estimate that 42% of all the lives saved with statin therapy were from a reduction in death from lung cancer specifi cally. That statins reduce the risk of lung cancer or deaths from lung cancer is consistent with the literature 2 and concurs with our understanding of the adverse effects of sys temic infl ammation on epithelial cancers. 2 -4 Moreover, Arimura and colleagues 5 recently showed that systemic infl ammation was responsible for DNA damage in the airways of mice and was mediated through macrophages, further implicating systemic infl ammation in lung cancer (reverse effect) ( Fig 1 ) . We conclude that statin therapy provides a powerful immunomodulatory action that has a profound effect on the innate immune system in the lung, specifi cally cytokine-driven infl ammation that characterizes aeropollutant-based airways disease (ie, COPD and its comorbidities). We suggest that it is time to examine statins as adjunct therapy to inhaler-based treatment in COPD.
Routine Pneumocystis Pneumonia Prophylaxis in Patients Treated With Rituximab ?
To the Editor:
I was pleased to read the article by Martin-Garrido et al 1 in this issue of CHEST (see page 258) on Pneumocystis pneumonia (PcP) risk in patients treated with rituximab at the Mayo Clinic in Rochester, Minnesota, from 1998 to 2011. Thirty of 230 patients with PcP had received rituximab, compared with 23 patients with HIV-associated PcP. 1 However, to determine the incidence of PcP in patients treated with rituximab, I would like to know how many patients were treated with rituximab during the study period.
A systematic review and meta-analysis of randomized controlled trials recommended PcP prophylaxis in patients without HIV infection when the risk for PcP is . 3.5%. 2 In transplantation medicine, routine PcP prophylaxis is used in patient groups with a fi xed, high incidence of disease . 3% to 5%. 3 PcP incidence in patients treated with rituximab is, therefore, of clinical importance to assess the risk-benefi t ratio of routine, primary PcP prophylaxis. I agree with the authors that primary PcP prophylaxis should be considered in patients treated with rituximab, 1 but not solely for the duration of B-cell depletion.
